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Abstract 
The main aim of this study was to objectify the treatment assignment criteria used in a 
clinical centre for addiction treatment in Spain. A sample of 162 patients (87 inpatients 
and 75 outpatients) who sought treatment between 2010 and 2012 was assessed. 
Clinical characteristics (addiction severity, psychopathological symptoms, 
impulsiveness and maladjustment) of the two treatment groups (inpatient and 
outpatient) into which patients were assigned according to the clinical criteria of 
therapists were analysed to identify which variables were more relevant for patient 
placement. Moreover, the therapeutic progression of patients who met and did not meet 
the assignment criteria received was studied. According to the results, a score above 4 in 
the family/social support area of the European Addiction Severity Index (EuropASI), or, 
in cases of a score between 2 and 4 in the family/social area of EuropASI, a score above 
2 in the partner subscale of the Maladjustment Scale correctly classified 73.5% of cases 
(96.6% of inpatients and 46.7% of outpatients). Comparisons of therapeutic results 
depending on matching or mismatching these assignment criteria showed a larger effect 
size in mismatching patient assignment criteria for outpatient treatment. The results 
obtained in this study provide an objective criterion for addicted patient placement. 
Moreover, from a cost-effective perspective, they question the necessity of inpatient 
treatment in most cases, demonstrating that outpatient treatment is a sufficient level of 
care. This study addresses the approach to assigning patients to the treatment modality 
that best fits them, implementing the least expensive level of care needed to achieve 
treatment success. 
Keywords: Drug addiction; therapeutic assignment criteria; therapeutic community; 
outpatient treatment; effectiveness. 
3 
Journal of Substance Abuse Treatment, 2017, 76, 28-35 
http://dx.doi.org/10.1016/j.jsat.2017.02.014 
  
4 
Journal of Substance Abuse Treatment, 2017, 76, 28-35 
http://dx.doi.org/10.1016/j.jsat.2017.02.014 
1. Introduction 
The cost-effectiveness of treatment for alcohol and drug abuse disorders is 
currently an important challenge in the field of addictions. Adequate treatment matching 
based on empirically established patient placement criteria becomes relevant to 
optimally provide cost- and outcome-effective treatment (McGee & MeeLee, 1997). 
The correct assignment to an inpatient or outpatient treatment modality based on the 
needs of patients is critical in optimizing the clinical intervention provided. 
The literature about addiction treatment effectiveness explains that both inpatient 
and outpatient modalities have empirical evidence supporting their effectiveness 
(Fernández-Montalvo & López-Goñi, 2010; Fernández-Montalvo, López-Goñi, Illescas, 
Landa, & Lorea, 2008; Hubbard, Craddock, & Anderson, 2003; Magor-Blatch, Bhullar, 
Thomson, & Thorsteinsson, 2014; McCarty et al., 2014; Reif et al., 2014; 
Vanderplassschen et al., 2013; Wallace & Weeks, 2004). However, research with 
greater specificity and consistency is needed, taking into account the heterogeneity of 
both inpatient (e.g. therapeutic community versus short-term residential treatments) and 
outpatient (e.g. regular versus intensive) treatment programmes. 
In clinical settings, the decision about which treatment modality (outpatient or 
inpatient) is the most appropriate for each patient is often based on the subjective 
criteria of therapeutic teams. There is an important lack of objective clinical criteria 
matching patients to the type of treatment best suited to their needs. Therapists use their 
clinical impression of the patient’s situation and tend to assign inpatient treatment to 
those with more severe addictions as well as those who do not have good family or 
partner support to help them in the recovery process (Gregoire, 2000; Harrison & 
Asche, 1999). Another common criterion used to assign inpatient treatment is the lack 
of satisfactory results in outpatient programmes. Patients with frequent episodes of 
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relapse or high dropout rates in outpatient treatment are usually moved to inpatient 
programmes (Gregoire, 2000; López-Goñi, Fernández-Montalvo, Cacho, & Arteaga, 
2014). 
However, it is necessary to determine objective criteria beyond the clinical 
impression of therapists that will enable decision making based on empirical evidence 
when assigning patients to the most appropriate treatment modality. Although there 
have been some attempts to establish objective patient placement criteria (American 
Society of Addiction Medicine, 1996; Hoffman, Halikas, Mee-Lee, & Weedman, 1991; 
McGee & MeeLee, 1997; McKay, Cacciola, McLellan, Alterman, & Wirtz, 1997; 
Stallvik, Gastfriend, & Nordahl, 2015), there is still not a scientific consensus on which 
criteria should be taken into account to place patients in the best level of care. This is an 
important issue because one of the main challenges in the treatment of addictions 
focuses on matching treatment to the specific needs of each patient (Camilleri, Cacciola, 
& Jenson, 2012; Gregoire, 2000; McGee & MeeLee, 1997; McKay et al., 1997; Rohrig, 
Buchholz, Wahl, & Berner, 2015). 
Therefore, the main purposes of this naturalistic study were to objectify the 
treatment assignment criteria used in a clinical centre for addictions in Spain and to 
evaluate the subsequent treatment progression. The specific goals were first, to analyse 
the clinical characteristics (addiction severity, psychopathological symptoms, 
impulsiveness and maladjustment) of two treatment groups (inpatient and outpatient) in 
which patients were assigned according to the clinical criteria of therapists; second, to 
identify which variables were more relevant in the therapeutic assignment of patients; 
third, to determine the differential progression of both treatment groups to evaluate the 
utility of the assignment criteria; and fourth, to compare the therapeutic progression 
between patients who met and did not meet the assignment criteria. 
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2. Methods 
The protocol for this study was approved by the ethics committees of the 
Universidad Pública de Navarra and the Fundación Proyecto Hombre de Navarra. 
Written informed consent was signed by all participants. 
2.1 Participants 
The initial sample consisted of 227 patients seeking treatment for addiction in 
the Proyecto Hombre de Navarra addiction treatment programme (Spain) from May 
2010 to December 2012. This programme, which offers two modalities of intervention 
(outpatient and inpatient), is public and attends to patients from all over the region and 
who are representative of Spanish patients with addiction problems. Payment for 
treatment is not required. Every patient who consecutively attended the clinical centre 
was considered for study inclusion. 
Study admission criteria included the following: a) meeting the diagnostic 
criteria for substance dependence disorder according to DSM-IV-TR (American 
Psychiatric Association, 2000), b) being between 18 and 65 years old, c) beginning the 
assigned treatment for drug-addiction, and d) giving consent to participation in the 
study. Following the above mentioned admission criteria, 46 people (20.3%) were 
excluded from the study and 19 (8.4%) refused to participate in the study. The reasons 
for exclusion were: a) not meeting DSM-IV-TR criteria for substance dependence (13 
cases), b) refusing to receive treatment (13 cases), c) being derived to other service 
because of different reasons (11 cases), and d) being older that 65 (9 cases). Therefore, a 
total of 162 (71.4% of total) subjects were studied.  
2.2 Instruments 
 The instruments used in this study formed part of the clinical centre assessment 
package, and therefore they were not specifically selected for this research. 
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The EuropASI (Kokkevi & Hartgers, 1995) is the European version of the 
Addiction Severity Index scale (ASI) (McLellan, Luborsky, Woody, & O´Brien, 1980). 
In this study, the Spanish version by Bobes, González, Sáiz, and Bousoño (1996) was 
employed. This interview assesses seven different areas: general medical condition, 
employment situation, alcohol consumption, use of other drugs, legal problems, family 
and social relationships, and psychological state. In this study, the Interviewer Severity 
Rating (ISR) was used. These ratings have shown their usefulness in different studies 
developed in treatment settings (López-Goñi, Fernández-Montalvo, & Arteaga, 2012; 
López-Goñi et al., 2010). Although the Composite Scores provided by this instrument 
are usually used in the research field, in Spain the studies of López-Goñi et al. (2012) 
showed the utility of the ISRs for research purposes. Each area ranges from 0 (no 
problem) to 9 (extreme problem). The higher the score, the more need for treatment. 
The one-week test-retest reliabilities ranged from 0.67 to 0.96 in the seven different 
areas (González et al., 2002).  
The Symptom Checklist (SCL-90-R) (Derogatis, 1992) is a self-report that 
assesses psychopathological symptoms. It is composed of 90 items, which are answered 
in a five-point Likert scale, from 0 (nothing) to 4 (extremely). It is comprised of nine 
primary symptom dimensions (somatisation, obsession-compulsion, interpersonal 
sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, and 
psychoticism), and of three global indices of severity (the Global Severity Index (GSI), 
which reflects overall symptom severity, the Positive Symptom Distress Index (PSDI), 
which indicates symptom intensity, and the Positive Symptom Total (PST), which 
includes the number of items answered with a score different from 0). The internal 
consistency ranges from .70 to .90. In this study, the percentiles of each dimension have 
been considered.  
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The Barratt Impulsiveness Scale (BIS-10) (Barratt, 1985) aims to assess the 
degree of impulsivity of the subjects. It consists of 33 items scoring from 0 to 4 on a 
five-point Likert scale, and is composed of three factors having each one 11 items: 
motor, cognitive and non-planning impulsiveness. The total score ranges from 0 to 132 
(the higher the score, the greater impulsiveness). The internal consistence is .84. 
The Maladjustment Scale (Echeburúa, Corral, & Fernández-Montalvo, 2000) 
reveals how each patient is affected in six different areas of everyday life (labour, 
social, leisure, partner, family and general). Each area ranges from 0 (nothing) to 5 
(extremely) on a six-point Likert scale. The total scale range is 0-30. The higher the 
score, the higher the level of maladjustment. The internal consistency is .94. 
2.3 Treatment modalities 
Outpatient treatment. This is a cognitive-behavioural programme aimed at 
abstinence. The main therapeutic techniques are stimulus control, in vivo exposure and 
relapse prevention. Successful programme completion usually requires 12 months. The 
treatment includes weekly sessions (45-60 minutes) during the first 6 months, and 
biweekly sessions during the rest of time. The effectiveness of this programme in the 
addiction treatment has been proven (Fernández-Montalvo & López-Goñi, 2010). 
Inpatient treatment. This treatment comprises 2 therapeutic phases: residential 
therapeutic community and reinsertion. The first phase (therapeutic community), which 
has an estimated duration of 1 year, is inpatient-based and has 2 main goals: a) to 
develop or modify behaviours that will increase personal autonomy, and b) to learn 
coping skills to achieve relapse prevention. In this phase, group and occupational 
therapies are provided. The second phase (reinsertion), with a duration of approximately 
half a year, consists in a progressive reduction in the intensity of treatment. The goal of 
this phase is the reinsertion in social, family and employment areas through individual 
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and group therapies on an outpatient basis. Successful programme completion usually 
requires 18 months. The effectiveness of this programme in the addiction treatment has 
been proven (Fernández-Montalvo et al., 2008). 
Both programmes take into account the patients’ family, involving the family 
members in the recovery process and giving them specific support to deal with the 
patient through specific support groups. Anyway, it is not compulsory the family 
participation to provide treatment to the patient. 
2.4 Experimental design 
A two-group experimental design (with two treatment groups for addiction) with 
repeated measures (pretreatment and 6-month follow-up) was used. The first group 
received outpatient treatment and the second group received inpatient (therapeutic 
community) intervention. 
2.5 Procedure 
All patients were interviewed and treated by clinical psychologists with ten or 
more years of experience in assessing and treating addictions. 
The assessment of the sample was carried out in two sessions before beginning 
the treatment for addiction. Self-report questionnaires were administered with the 
presence and support of the interviewers. The sessions occurred once per week, and the 
time interval between sessions was the same for each participant. In the first session, 
data related to socio-demographic characteristics and drug consumption were assessed 
by the EuropASI. In the second session, questionnaires that assessed other variables 
(psychopathological symptoms, personality characteristics and maladjustment) were 
administered. 
Once the clinical sample was assessed, patients were assigned to one of the two 
treatment modalities of the programme (outpatient or inpatient treatment) following the 
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usual criteria of the clinical centre. Generally, patients with severely high consumption 
and without family or partner support tended to receive the inpatient treatment. In 
contrast, patients with a better partner and/or family support structure usually received 
the outpatient treatment. These assignment criteria were based on clinical impressions 
of the therapeutic team. 
The next evaluation, always in the format of a personal interview, took place at 
the 6-month follow-up after finishing the whole treatment, using the same instruments.  
2.6 Data Analysis 
 Descriptive analyses were performed for all variables. In the bivariate analysis, 
χ2 or Student’s t test for independent samples were used depending on the nature of the 
variables analysed. Effect size (Cohen’s d or w) for all of the analyses were provided, 
taking into account Cohen’s recommendation (Cohen, 1988): d = 0.20 (small effect 
size), d = 0.50 (medium effect size) and d = 0.80 (large effect size). Regarding 
multivariate analysis, a Chi-squared Automatic Interaction Detection (CHAID) analysis 
with all the studied pretreatment variables was conducted to identify the main variables 
related to treatment assignment. This test evaluates the discriminant capacity of several 
independent variables over a dependent variable (in this study, assignment to inpatient 
or outpatient treatment), and it provides cut-offs for each variable defining the best-fit 
profile for both groups. Differences between groups in the effect size were calculated to 
establish which group presented a higher improvement. A difference of p < .05 was 
considered significant. All statistical analyses were performed using SPSS (vs. 23.0) 
software. 
3. Results 
3.1 Characteristics of the sample 
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Of the 162 subjects studied, 73.5% were men (n = 119) and 26.5% were women 
(n = 43). Of this sample, 53.7% (87 patients) were assigned to inpatient treatment 
(therapeutic community). The rest of patients (n = 75; 46.3%) received the outpatient 
programme.  
The average age of the subjects was 36.4 years (SD = 8.9). The socioeconomic 
levels were middle to lower-middle class. The main substances that motivated treatment 
were cocaine and other stimulants (39.3% of the sample) and alcohol (32.7%). Other 
substances (e.g., heroin, cannabis, amphetamine, etc.) showed lower incidences but 
affected a total of 28% of the sample. Most of the subjects were single (63.8%). 
Concerning education level, 47.9% had only primary studies, 44.7% had secondary 
studies, and 7.4% had a university degree. 
3.2 Comparisons between groups in the pretreatment variables 
 Regarding sociodemographic variables (Table 1), significant differences 
between groups were found in marital status and education level. Generally, patients in 
the therapeutic community presented with a higher rate of separation/divorce and with a 
lower educational level.  
PLACE TABLE 1 HERE 
 Although inpatients showed greater alcohol consumption and outpatients greater 
cocaine consumption, there were no statistically significant differences between groups 
in terms of the substance that motivated their treatment (Table 1). However, as was 
expected, patients assigned to the therapeutic community scored significantly higher in 
most of the severity areas assessed by the EuropASI (Table 2). The effect sizes were 
large (above .80) in two areas: Family/Social and Medical. 
PLACE TABLE 2 HERE 
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 From a psychopathological perspective, patients assigned to the therapeutic 
community tended to have a greater severity in the SCL-90-R, the Psychiatric area of 
the EuropASI and the BIS-10. Significant differences were found in depression (SCL-
90-R) and Psychiatry scale (EuropASI), but with a small effect size. 
 Finally, patients receiving an inpatient treatment in the therapeutic community 
showed statistically significant higher levels of maladjustment to everyday life in 4 out 
of the 6 areas assessed by the Maladjustment Scale. The effect sizes for these variables 
were small to medium. 
3.3 Objectifying patient placement criteria 
 A CHAID analysis was conducted to find which variables were more relevant to 
becoming an objective criterion for the therapeutic assignment of patients. The results 
from this CHAID analysis showed that two variables (family/social support and partner 
maladjustment) were the most relevant (Figure 1). 
PLACE FIGURE 1 HERE 
 Specifically, a score above 4 in the family/social support area of the EuropASI 
or in those cases with a score between 2 and 4 in the family/social area of EuropASI, a 
score above 2 in the partner subscale of the Maladjustment Scale correctly classified 
73.5% of cases (96.6% of inpatients and 46.7% of outpatients). 
3.4 Comparison between groups in therapeutic progression  
 The results for repeated measurements analyses of the studied variables are 
shown in Table 3. Regarding inpatient treatment, the data showed that this group 
achieved statistically significant improvement in almost all the variables related to 
addiction severity, psychopathological symptoms, impulsiveness and maladjustment. 
Most of them presented medium to large effect sizes.  
PLACE TABLE 3 HERE 
13 
Journal of Substance Abuse Treatment, 2017, 76, 28-35 
http://dx.doi.org/10.1016/j.jsat.2017.02.014 
 On the other hand, patients in outpatient treatment also achieved significant 
improvement in most of the variables studied. As in the inpatient group, the effect sizes 
for these variables were medium to large. 
 Once the progression of both treatment groups was analysed separately, 
differences between groups in the effect sizes were calculated to establish which group 
presented a higher improvement in the variables studied. The results showed that the 
improvement of both groups in psychopathological symptoms and impulsiveness was 
similar, although the effect sizes in the inpatient treatment group tended to be higher 
(Table 3). The main differences in the effect sizes were found in addiction severity 
(medical, alcohol, and family/social areas) and maladjustment (labour and family areas). 
In the rest of the variables, there were no relevant differences in the effect sizes. 
3.5 Differential therapeutic results depending on matching or mismatching the 
assignment criteria 
 Several analyses were conducted to determine whether patients who were treated 
in the appropriate level of care according to the objective criteria obtained better 
outcomes than patients who were not. In the case of inpatient treatment, most of the 
patients (96.6%) matched the obtained criteria and only 3.4% of cases did not meet the 
criteria for inpatient treatment. In the case of outpatient treatment, the rate of patients 
who met the criteria was 46.7% and 53.3% did not. As there were only 3 patients 
mismatching the assignment criteria for inpatient treatment, the analyses were carried 
out only for outpatient treatment. The results obtained are shown in Table 4. 
PLACE TABLE 4 HERE 
 Generally, the results showed that patients who met the criteria for outpatient 
treatment achieved small to medium effect sizes in most of the variables, and patients 
who did not meet the criteria achieved medium to large effect sizes. The repeated-
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measures analyses indicated that patients who mismatched outpatient treatment (i.e. 
patients who actually met criteria for inpatient treatment) obtained greater statistically 
significant improvements in variables related to addiction severity, psychopathological 
symptoms, impulsiveness and maladjustment. 
4. Discussion 
 In this naturalistic study, the profiles of patients receiving two different 
treatment modalities (inpatient or outpatient) have been compared to objectify the 
treatment assignment criteria used in a clinical centre. Due to the assignment method 
used by clinical professionals (based on their clinical perception), both groups of 
addictive patients presented significant differences between them in terms of socio-
demographic, psychopathological and adjustment variables. After conducting statistical 
analyses, two objective variables supported the clinical assignment to both groups, 
family/social support (EuropASI) and partner maladjustment (Maladjustment Scale). 
This finding is relevant because it provides clinical professionals who work in addiction 
treatment centres with an objective criterion to make decisions about how to assign 
patients to the treatment modality that best fits them. 
 The two variables obtained as relevant assignment criteria support the results of 
previous studies showing that patients characterized by more severe substance use 
disorders, coexisting psychosocial problems, and weaker social and partner supports 
tended to be treated in inpatient programmes (Camilleri et al., 2012; Gregoire, 2000; 
Harrison & Asche, 1999; Magor-Blatch et al., 2014; McGee & MeeLee, 1997; McKay 
et al., 1997; Reif et al., 2014). Therefore, the psychosocial and partner consequences of 
the addiction problem become crucial variables when designing the therapeutic 
approach. The results of this study emphasize the need of following these objective 
matching criteria when clinicians assign patients to treatments, beyond the clinical 
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impression and the general idea that patients with higher addiction severity or worse 
psychiatric status should be treated in an inpatient setting. 
 On the other hand, in this study, the EuropASI has become a useful instrument 
to objectify clinical decisions about the treatment that better meets patient needs. The 
use of standardized assessments as methods for placement matching of patients with 
addiction problems has been shown to be useful in other studies (Camilleri et al., 2012; 
Rohrig et al., 2015). Regardless, the EuropASI assesses both family and social problems 
in one only area. The results obtained in this study support previous literature that 
indicated the relevance of assessing both dimensions separately to identify more 
accurately specific needs in these areas (López-Goñi et al., 2012). 
 The analysis of the therapeutic progression of patients belonging to both 
inpatient and outpatient treatment programmes has shown effect sizes that range from 
medium to large. Both treatment groups show statistically significant differences from 
the pretreatment to the follow-up assessment in most of the variables studied. Similar 
results have been obtained in previous studies that compare inpatient and outpatient 
treatment for patients with addiction problems (Harrison & Asche, 1999). In this study, 
the patients who benefit most from both programmes are those presenting with a more 
severe addiction problem. These results are related directly to an important question in 
addiction treatment: what is the most cost-effective treatment? Although many studies 
comparing inpatient and outpatient treatment outcomes have been conducted (Harrison 
& Asche, 1999; Magor-Blatch et al., 2014; McCarty et al., 2014; Miller & Hester, 1986; 
Rohrig et al., 2015; Schmidt et al., 2009), no study to date has produced convincing 
evidence that treatment in residential settings is more effective than outpatient 
treatment. 
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 In this study, 53.3% of the patients receiving outpatient treatment met the 
objective criteria obtained to receive inpatient treatment in the therapeutic community. 
Although they were mismatched into the outpatient treatment group, the effect sizes 
achieved were even greater than those obtained by patients who met the criteria for 
outpatient treatment. Previous studies with patient matching and mismatching the 
assignment criteria have also shown no differences between patients in the results 
obtained (McCarty et al., 2014; McKay et al., 1997). In this study, the good results 
obtained in the outpatient programme by patients who met the criteria for inpatient 
treatment questions the necessity of the inpatient treatment in these cases, as the 
outpatient treatment appears to be a sufficient level of care. These results should be 
taken into account because the use of inpatient hospital or residential settings 
contributes substantially to the cost of the treatment of patients with addiction problems. 
 This study has a number of limitations. First, one aspect that should be 
considered is the distribution of the sample by gender. Just a few women were included 
and, therefore, the conclusions of the study are mainly referred to male patients with 
addiction problems. Although this is a common circumstance in most of the studies 
about addictions, it should be taken into account when generalising the obtained results.  
 A second limitation is related to the type of drug that motivated treatment. A larger 
sample size would allow the analysis of differential results depending on the type of 
substance used. Third, in this study, the motivation for seeking treatment has not been 
analysed. It would be interesting to include specific measures of treatment motivation in 
future studies. However, in this research the instruments used formed part of the clinical 
centre assessment package, and therefore they were not specifically selected for this 
study. On the other hand, some patients probably present a differential preference to 
receiving treatment in an outpatient or inpatient basis depending on their psychosocial 
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and family situation. It would be desirable to explore the influence of this differential 
preference on the results of both programmes. Finally, the inpatient programme studied 
in this research is a long-term therapeutic community. It may create a bias that prevents 
us from generalizing the results to other types of shorter stay residential treatments.  
 Regardless, the strengths of this research are related to its naturalistic design and 
to the use of standardized instruments to objectify the assignment criteria for drug-
addicted patients. Being a naturalistic study, patients were not randomly assigned to a 
group but rather were placed into treatment based on clinical considerations. The 
establishment of objective patient placement criteria represents an approach to matching 
patients with addiction problems to the least expensive level of care needed to achieve 
treatment success. This is a necessary research topic due to shrinking treatment 
resources for addicted patients. 
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Table 1 
Comparisons of socio-demographic and consumption variables 
 
 Total (N = 162) 
Therapeutic 
community 
(n = 87) 
Outpatient 
treatment 
(n = 75) 
 
  
 Mean SD Mean SD Mean SD t        df p d 
Age  36.4 8.9 37.3 9.1 35.2 8.5 1.4  145 .160 0.23 
 N (%) n (%) n (%) X2     df p w 
Gender          
Men 119 73.5% 63 72.4% 56 74.7% 0.1   1 .746 0.06 Women 43 26.5% 24 27.6% 19 25.3% 
Marital status          
Single 97 63.8% 48 59.3% 49 69.0% 
8.9   2 .012 0.43 Married 30 19.7% 13 16.0% 17 23.9% 
Separated/Divorced 25 16.5% 20 24.7% 5 7.0% 
Education level          
Primary 58 47.9% 35 59.3% 23 37.1% 
7.3   2 .026 0.51 Secondary 54 44.7% 19 32.2% 35 56.5% 
University 9 7.4% 5 8.5% 4 6.5% 
Substance motivating 
treatment       
   
Alcohol 49 32.7% 31 38.3% 18 26.1% 
2.7   2 .252 0.27 Cocaine 59 39.3% 28 34.6% 31 44.9% 
Other 42 28.0% 22 27.1% 20 28.9% 
SD = standard deviation; df = degree of freedom; d = Cohen´s d; w = Cohen´s w 
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Table 2 
Comparisons of severity of addiction, psychopathological symptoms, personality 
characteristics and maladjustment variables 
 
 
Total 
N = 162 
Therapeutic 
community 
(n = 87) 
Outpatient 
treatment 
(n = 75)     
 M SD M SD M SD t df p d 
EuropASI           
Medical 2.83 1.83 3.56 1.97 2.00 1.21 5.8 150 <.001 0.85 
Employment/Support 3.61 1.94 4.28 1.93 2.85 1.67 4.9 150 <.001 0.74 
Alcohol  4.39 2.17 5.01 2.15 3.67 1.96 4.0 149 <.001 0.62 
Use of other drugs 4.44 2.06 4.69 2.38 4.14 1.59 1.6 149 .103 0.27 
Legal 2.64 1.99 2.72 2.19 2.56 1.74 0.5 150 .638 0.08 
Family/Social 4.67 1.85 5.53 1.67 3.69 1.55 7.0 150 <.001 0.99 
Psychiatric 4.27 1.71 4.59 1.72 3.90 1.64 2.5 150 .012 0.40 
SCL-90-R           
Global Severity Index 70.0   31.5 74.67 28.48 64.61 34.09 1.9 123.3 .065 0.32 
Positive Symptom Distress 
Index 49.9   30.2 52.70 30.80 46.61 29.40 1.2 135 .240 0.20 
Positive Symptom Total 74.0   29.3 77.62 26.41 69.95 32.01 1.5 135 .127 0.26 
Somatisation 62.4   31.4 64.58 29.75 60.55 33.41 0.7 135 .457 0.13 
Obsession-compulsion 64.1   32.5 65.86 30.89 62.72 34.65 0.6 135 .575 0.10 
Interpersonal sensitivity 68.2   31.1 73.29 28.95 62.84 32.93 2.0 126.5 .052 0.33 
Depression 67.9   30.5 73.97 25.77 61.17 34.27 2.4 116.0 .016 0.42 
Anxiety 64.7   32.9 69.99 29.88 59.16 35.61 1.9 123.6 .058 0.33 
Hostility 54.0   33.0 57.44 31.92 50.05 34.07 1.3 135 .192 0.22 
Phobic anxiety 52.0   39.1 55.01 38.32 48.84 40.20 0.9 135 .360 0.16 
Paranoid ideation 67.7   32.2 72.12 30.09 63.27 34.24 1.6 135 .109 0.27 
Psychoticism 71.2   30.1 75.40 28.63 66.64 31.50 1.7 135 .091 0.29 
BIS           
Motor impulsiveness 18.93 8.04 19.52 7.79 18.24 8.33 1.0 160 .315 0.16 
Attentional impulsiveness 21.33 6.14 21.48 6.21 21.16 6.10 0.3 160 .740 0.05 
Non-planning impulsiveness 17.81 6.76 18.75 6.64 16.73 6.78 1.9 160 .058 0.30 
Total impulsiveness 58.07 17.25 59.75 17.25 56.13 17.16 1.3 160 .185 0.21 
Maladjustment         
Labour 3.07 1.76 3.37 1.59 2.72 1.88 2.4 160.0 .019 0.37 
Social 3.17 1.50 3.38 1.33 2.92 1.64 2.0 160.0 .051 0.31 
Leisure  3.23 1.47 3.39 1.31 3.04 1.63 1.5 141.3 .137 0.24 
Partner 3.28 1.64 3.59 1.39 2.92 1.84 2.6 132.4 .012 0.41 
Family 3.29 1.43 3.74 1.15 2.77 1.55 4.4 132.4 <.001 0.68 
General 3.75 1.25 4.01 1.06 3.45 1.38 2.9 136.0 .005 0.45 
Total maladjustment 19.70 7.23 21.47 6.19 17.65 7.83 3.4 140.2 .001 0.53 
SD = standard deviation; df = degree of freedom; d = Cohen´s d
26 
Journal of Substance Abuse Treatment, 2017, 76, 28-35 
http://dx.doi.org/10.1016/j.jsat.2017.02.014 
Table 3 
Results of the repeated-measures analyses (pretreatment and 6-month follow-up) and effect size 
 
 Inpatient treatment Outpatient treatment  
 Pretreatment Follow-up     Pretreatment Follow-up      
 M SD M SD t df p d M SD M SD t df p d d diff. 
EuropASI                  
Medical 3.74 1.60 1.94 1.87 4.3 33 <.001 0.96 1.77 0.99 1.52 1.48 1.2 30 .223 0.17 0.79 
Employment/Support 4.85 1.67 5.18 2.44 0.8 33 .422 -0.13 2.42 1.50 2.87 2.74 1.1 30 .260 -0.16 0.03 
Alcohol  5.85 1.83 3.21 2.33 5.3 33 <.001 1.13 3.81 1.89 2.23 2.20 3.6 30 .001 0.72 0.41 
Use of other drugs 4.53 2.53 2.44 2.71 5.2 33 <.001 0.77 3.87 1.59 2.13 2.28 4.5 30 <.001 0.77 0.00 
Legal 2.74 2.45 1.68 2.50 3.3 33 .002 0.42 2.26 1.50 1.23 1.78 3.6 30 .001 0.58 -0.16 
Family/Social 6.00 1.58 3.56 1.88 7.9 33 <.001 1.30 3.48 1.43 3.06 1.67 1.2 30 .235 0.25 1.05 
Psychiatric 4.82 1.55 3.09 2.57 4.1 33 <.001 0.67 3.97 1.49 2.26 2.13 5.1 30 <.001 0.80 -0.13 
SCL-90-R                  
Global Severity Index 75.13 30.27 53.35 38.80 4.6 47 <.001 0.56 65.09 34.05 51.30 37.86 2.6 42 .013 0.36 0.2 
Positive Symptom Distress Index 50.21 31.72 42.31 32.70 1.8 47 .071 0.24 47.70 30.09 37.53 31.08 2.1 42 .045 0.33 -0.09 
Positive Symptom Total 78.92 28.42 58.19 38.10 4.6 47 <.001 0.54 70.86 31.63 55.72 37.59 2.9 42 .006 0.40 0.14 
Somatisation 64.00 31.74 48.00 36.30 3.8 47 <.001 0.44 59.56 33.75 52.98 33.07 1.4 42 .182 0.20 0.24 
Obsession-compulsion 66.29 31.84 51.56 36.65 3.5 47 .001 0.40 66.72 34.11 50.60 36.51 3.4 42 .001 0.44 -0.04 
Interpersonal sensitivity 74.50 29.93 55.90 34.51 4.0 47 <.001 0.54 64.47 32.72 55.09 35.64 1.9 42 .070 0.26 0.28 
Depression 75.27 25.52 55.69 35.90 4.1 47 <.001 0.55 62.07 34.39 50.09 36.44 2.3 42 .026 0.33 0.22 
Anxiety 70.65 29.64 51.13 37.08 3.8 47 <.001 0.53 60.19 36.56 45.72 34.84 2.4 42 .019 0.42 0.11 
Hostility 60.56 30.10 42.33 35.66 4.2 47 <.001 0.51 50.05 34.31 35.26 32.93 2.4 42 .019 0.45 0.06 
Phobic anxiety 51.21 41.70 44.23 38.51 1.0 47 .308 0.18 48.19 42.57 40.14 40.24 1.4 42 .157 0.20 -0.02 
Paranoid ideation 76.52 26.57 60.50 36.22 3.4 47 .002 0.44 64.02 35.50 54.42 33.07 1.9 42 .065 0.29 0.15 
Psychoticism 76.06 29.58 60.27 38.12 3.3 47 .002 0.41 68.09 31.42 52.65 39.81 2.3 42 .028 0.39 0.02 
BIS                  
Motor impulsiveness 20.17 7.68 17.67 7.83 2.3 53 .023 0.32 18.04 8.57 17.06 6.81 0.9 46 .356 0.14 0.18 
Attentional impulsiveness 21.20 6.49 19.74 5.87 1.8 53 .070 0.25 20.32 6.13 19.77 5.21 0.8 46 .452 0.11 0.14 
Non-planning impulsiveness 18.83 6.72 15.80 7.74 3.3 53 .001 0.39 15.98 5.87 15.36 7.35 0.7 46 .458 0.08 0.31 
Total impulsiveness 60.20 17.66 53.20 19.11 3.3 53 .001 0.37 54.34 16.54 52.19 16.67 1.1 46 .264 0.13 0.24 
Maladjustment                  
Labour 3.54 1.48 1.61 1.64 6.7 53 <.001 1.17 2.74 1.85 1.64 1.58 4.0 46 <.001 0.70 0.47 
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Social 3.41 1.49 1.78 1.61 6.6 53 <.001 1.01 3.06 1.69 1.83 1.62 4.3 46 <.001 0.76 0.25 
Leisure  3.37 1.38 1.80 1.66 6.7 53 <.001 0.95 3.11 1.66 1.91 1.49 4.8 46 <.001 0.80 0.15 
Partner 3.63 1.35 1.85 1.71 6.8 53 <.001 1.04 3.23 1.87 1.81 1.70 4.3 46 <.001 0.84 0.2 
Family 3.78 1.08 1.72 1.51 8.2 53 <.001 1.36 2.79 1.56 1.53 1.53 3.9 46 <.001 0.82 0.54 
General 3.98 1.07 2.00 1.63 8.7 53 <.001 1.22 3.53 1.41 2.06 1.69 5.3 46 <.001 0.87 0.35 
Total maladjustment 21.70 5.93 10.76 8.22 9.2 53 <.001 1.33 18.47 7.99 10.79 8.00 5.5 46 <.001 0.96 0.37 
 
SD = standard deviation; df = degree of freedom; d = Cohen´s d 
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Table 4 
Results of the repeated-measures analyses (pretreatment and 6-month follow-up) and effect size (outpatients) 
 
 Matching criteria Mismatching criteria  
 Pretreatment Follow-up     Pretreatment Follow-up      
 M SD M SD t df p d M SD M SD t df p d d diff. 
EuropASI                  
Medical 1.64 1.15 1.36 1.44 1.1 13 .302 0.24 1.88 0.85 1.65 1.53 7.4 16 .466 0.27 -0.03 
Employment/Support 2.21 1.37 2.36 2.62 0.2 13 .789 -0.10 2.59 1.62 3.29 2.84 1.2 16 .241 -0.43 0.33 
Alcohol  3.71 2.12 2.14 1.56 2.4 13 .032 0.74 3.88 1.72 2.29 2.66 2.6 16 .018 0.92 -0.18 
Use of other drugs 3.57 1.65 2.86 2.62 1.2 13 .253 0.43 4.12 1.53 1.53 1.80 6.1 16 <.001 1.69 -1.26 
Legal 1.79 1.12 1.21 1.71 1.1 13 .263 0.51 2.65 1.69 1.24 1.88 4.5 16 <.001 0.83 -0.32 
Family/Social 2.43 0.93 2.93 1.63 1.3 13 .221 -0.53 4.35 1.17 3.18 1.74 2.4 16 .026 1.00 -1.53 
Psychiatric 3.21 1.42 2.07 1.73 3.3 13 .006 0.80 4.59 1.27 2.41 2.45 4.1 16 .001 1.71 -0.91 
SCL-90-R                  
Global Severity Index 57.18 31.74 50.82 40.64 0.6 16 .503 0.20 70.27 35.09 51.61 36.75 2.9 25 .007 0.53 -0.33 
Positive Symptom Distress Index 38.18 30.64 32.64 29.96 0.7 16 .453 0.18 53.92 28.62 40.73 31.95 1.9 25 .060 0.46 -0.28 
Positive Symptom Total 67.29 29.99 56.23 40.47 1.1 16 .271 0.36 73.19 33.02 55.38 36.39 2.9 25 .007 0.53 -0.17 
Somatisation 48.12 34.12 44.00 36.15 0.5 16 .637 0.12 67.04 31.95 58.84 30.16 1.4 25 .175 0.25 -0.13 
Obsession-compulsion 57.88 35.88 50.82 36.48 0.8 16 .394 0.19 72.50 32.30 50.46 37.24 3.9 25 .001 0.68 -0.49 
Interpersonal sensitivity 51.88 31.20 48.17 41.24 0.3 16 .717 0.11 72.69 31.57 59.61 31.49 2.5 25 .018 0.41 -0.3 
Depression 50.71 34.35 46.29 37.48 0.5 16 .636 0.12 69.50 32.96 52.57 36.27 2.8 25 .010 0.51 -0.39 
Anxiety 55.41 33.98 47.58 38.19 0.7 16 .469 0.23 63.31 38.47 44.50 33.18 2.6 25 .013 0.48 -0.25 
Hostility 41.59 33.08 39.11 36.20 0.2 16 .817 0.07 55.58 34.59 32.73 31.08 3.2 25 .003 0.66 -0.59 
Phobic anxiety 41.12 42.05 49.35 43.59 1.0 16 .332 -0.19 52.81 43.08 34.11 37.53 2.7 25 .012 0.43 -0.62 
Paranoid ideation 59.47 33.49 55.82 33.71 0.4 16 .688 0.10 67.00 37.09 53.50 33.28 2.2 25 .034 0.36 -0.26 
Psychoticism 67.18 24.06 56.05 41.08 1.0 16 .308 0.46 68.69 35.88 50.42 39.61 2.0 25 .052 0.50 -0.04 
BIS                  
Motor impulsiveness 17.83 8.23 19.05 6.44 0.7 17 .459 -0.14 18.17 8.92 15.82 6.84 1.7 28 .090 0.26 -0.4 
Attentional impulsiveness 21.06 5.62 21.55 5.41 0.4 17 .676 -0.08 19.86 6.47 18.65 4.84 1.3 28 .203 0.18 -0.26 
Non-planning impulsiveness 16.67 6.26 17.72 7.27 0.8 17 .435 -0.16 15.55 5.68 13.89 7.13 1.6 28 .118 0.29 -0.45 
Total impulsiveness 55.56 16.67 58.33 16.43 0.8 17 .387 -0.16 53.59 16.70 48.37 15.90 2.3 28 .028 0.31 -0.47 
Maladjustment                  
Labour 2.56 2.01 1.66 1.74 1.8 17 .088 0.44 2.86 1.76 1.62 1.49 3.7 28 .001 0.70 -0.26 
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Social 2.72 1.87 1.72 1.52 2.3 17 .032 0.53 3.28 1.55 1.89 1.69 3.6 28 .001 0.89 -0.36 
Leisure  2.50 1.75 1.50 1.20 2.4 17 .024 0.57 3.48 1.50 2.17 1.60 4.1 28 <.001 0.87 -0.3 
Partner 1.72 1.70 1.33 1.60 0.7 17 .493 0.22 4.17 1.25 2.10 1.71 5.5 28 <.001 1.65 -1.43 
Family 2.22 1.66 1.33 1.53 1.7 17 .096 0.53 3.14 1.40 1.65 1.54 3.6 28 .001 1.06 -0.53 
General 2.94 1.55 1.88 1.77 3.0 17 .007 0.68 3.90 1.20 2.17 1.65 4.3 28 <.001 1.44 -0.76 
Total maladjustment 14.67 8.55 9.44 7.69 2.3 17 .031 0.61 20.83 6.73 11.62 8.20 5.1 28 <.001 1.36 -0.75 
 
SD = standard deviation; df = degree of freedom; d = Cohen´s d 
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Figure 1 Results of CHAID analyses 
 
